KEBBA LOBBA: Open Payments
NPI 1811656887 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$866 in 28 payments from 10 companies in 2025. Trend: 2023 $232 · 2024 $930 · 2025 $866
Food & beverage: $866
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $160 |
| Janssen Pharmaceuticals, Inc | 1 | $150 |
| Alkermes, Inc. | 1 | $113 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 1 | $84 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Lundbeck LLC | 1 | $25 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
Products named: VRAYLAR, INVEGA, LYBALVI, CAPLYTA, AUSTEDO XR, Auvelity, COBENFY, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
